Summary: The paper discusses the evolution of GINA experts’ recommendations throughout the years that concerns the usage of short acting β2-agonists (SABA) in bronchial asthma treatment. It is known for a long time that frequent use of SABA is associated with a greater risk of exacerbations and many evidences suggest benefits from replacing SABA with combination of inhaled corticosteroids with long acting β2-agonists ICS/LABA as reliever therapy. Authors analyze whether it is time to move away from the use of SABA in the treatment of asthma.